Publicaciones en colaboración con investigadores/as de Tel Aviv University (11)

2023

  1. Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion (American Journal of Clinical Dermatology, (2023), 24, 1, (5-14), 10.1007/s40257-022-00732-w)

    American Journal of Clinical Dermatology

  2. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023

    European Journal of Cancer, Vol. 195

  3. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion

    American Journal of Clinical Dermatology, Vol. 24, Núm. 1, pp. 5-14

2022

  1. Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides

    Dermatology (Basel, Switzerland), Vol. 238, Núm. 2, pp. 347-357

  2. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

    Blood, Vol. 140, Núm. 5, pp. 419-437

2021

  1. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*

    British Journal of Dermatology, Vol. 185, Núm. 5, pp. 1035-1044

  2. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

    British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730

2018

  1. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force

    European Journal of Cancer, Vol. 93, pp. 47-56

  2. Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome

    European Journal of Cancer

2015

  1. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3766-3773

2011

  1. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Blood